These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 26572073)

  • 1. Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?".
    El-Galaly TC; Hutchings M; Villa D
    Am J Hematol; 2016 Feb; 91(2):E2-3. PubMed ID: 26572073
    [No Abstract]   [Full Text] [Related]  

  • 2. Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?
    Adams HJ; Kwee TC
    Am J Hematol; 2016 Feb; 91(2):E1-2. PubMed ID: 26572499
    [No Abstract]   [Full Text] [Related]  

  • 3. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Importance of Bone Marrow Uptake on Baseline
    Soydal C; Koksoy EB; Yasar A; Turgal E; Erdogan BD; Akbulut H; Kucuk NO
    Cancer Biother Radiopharm; 2016 Dec; 31(10):361-365. PubMed ID: 27996313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Value of interim 18F-FDG PET-CT examination in evaluation of chemotherapy response and prognosis in patients with diffuse large B-cell lymphoma].
    Ding C; Li T; Fan L; Xu W; Li J; Sun J; Ding Q
    Zhonghua Xue Ye Xue Za Zhi; 2014 Apr; 35(4):342-4. PubMed ID: 24759025
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to H.J.A. Adams and T.C. Kwee.
    Mamot C
    J Clin Oncol; 2016 Mar; 34(7):766-7. PubMed ID: 26755512
    [No Abstract]   [Full Text] [Related]  

  • 7. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C; Li W; Liu C; He H; Bai O
    Blood Cells Mol Dis; 2016 Mar; 57():42-9. PubMed ID: 26852654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [¹⁸F-FDG PET/CT for predicting outcomes of diffuse large B-cell lymphoma: shall it be performed in the interim versus later phase of chemotherapy?].
    Li H; Wu H; Wang Q; Li H; Zhou W; Tian Y; Dong Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Feb; 35(2):208-12. PubMed ID: 25736114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma.
    Chin V; Fulham M; Hertzberg M; Jackson M; Lindeman R; Brighton T; Kidson-Gerber G; Wegner EA; Cheung C; MacCallum S; Williams J; Thompson SR
    J Med Imaging Radiat Oncol; 2018 Jun; 62(3):432-439. PubMed ID: 29577608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
    Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
    Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.
    Minamimoto R; Fayad L; Advani R; Vose J; Macapinlac H; Meza J; Hankins J; Mottaghy F; Juweid M; Quon A
    Radiology; 2016 Jul; 280(1):220-9. PubMed ID: 26854705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.
    Adams HJ; Nievelstein RA; Kwee TC
    Br J Haematol; 2015 Jul; 170(2):185-91. PubMed ID: 25833790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Tateishi U; Tatsumi M; Terauchi T; Ando K; Niitsu N; Kim WS; Suh C; Ogura M; Tobinai K
    Cancer Sci; 2015 Feb; 106(2):186-93. PubMed ID: 25495273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma.
    Gallicchio R; Mansueto G; Simeon V; Nardelli A; Guariglia R; Capacchione D; Soscia E; Pedicini P; Gattozzi D; Musto P; Storto G
    Eur J Haematol; 2014; 92(5):382-9. PubMed ID: 24428392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT is a pivotal imaging modality to diagnose rare intravascular large B-cell lymphoma: case report and review of literature.
    Colavolpe C; Ebbo M; Trousse D; Khibri H; Franques J; Chetaille B; Coso D; Ouvrier MJ; Gastaud L; Guedj E; Schleinitz N
    Hematol Oncol; 2015 Jun; 33(2):99-109. PubMed ID: 24850057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of diffuse large B-cell lymphoma].
    Gleissner B; Zwick C; Pfreundschuh M
    Dtsch Med Wochenschr; 2008 Sep; 133(36):1785-94; quiz 1795-6. PubMed ID: 18767006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas.
    Barrington SF; Mikhaeel NG
    Curr Hematol Malig Rep; 2016 Jun; 11(3):185-95. PubMed ID: 27095319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients.
    El-Galaly TC; Pedersen MB; Hutchings M; Mylam KJ; Madsen J; Gang AO; Bøgsted M; de Nully Brown P; Loft A; Nielsen AL; Hendel HW; Iyer V; Gormsen LC
    Am J Hematol; 2015 Nov; 90(11):975-80. PubMed ID: 26201505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to M. Gleeson et al.
    Nowakowski GS; Macon WR; Gascoyne RD; Witzig TE
    J Clin Oncol; 2015 Oct; 33(28):3216-7. PubMed ID: 26261258
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.